Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
The Necessity of a Multidisciplinary Approach Through the mCRPC Treatment Journey
Jessica E. Hawley M.D. M.S.
ASCO GU 2024: Reviewing Updated Practice Guidelines for Prostate Cancer
Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU
Neal Shore, MD
Prostate Cancer Care: Overcoming Challenges in Delivering Germline Testing to Veterans
Daniel Kwon, MD
Reducing the Burden of Cytomegalovirus in HCT: Optimal Strategy for Prevention
Roy F. Chemaly, MD, MPH
Key Tests That Play a Crucial Role in Accurately Diagnosing GU Cancers
Addressing Health Equity in Genitourinary Cancer Clinical Trials
Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
James M. Cleary, MD, PhD
Kathleen Madden, FNP, MSN, AOCNP, APHN
Treating Patients with NSCLC: Decision-Making and Surgical Considerations
Charles Turck, PharmD, BCPS, BCCCP
Ravi Rajaram, MD, MSC
An Exploration of Current and Emerging Therapies for mCRPC
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
Jonathan D. Schoenfeld, MD, MPhil, MPH
Robert L. Ferris, MD, PhD
Accelerating Evidence-Based Care in LA SCCHN
Ezra Cohen, MD, FRCPSC, FASCO
Sue S. Yom, MD, PhD
SABCS 2023: A Look into New Research for Inflammatory Breast Cancer
Filipa Lynce, MD
Inflammatory Breast Cancer: A New Scoring System Proposed
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
Christopher M. Gallagher, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.